Dr. Carol J. Levy, MD
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (1988)
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 47
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1988Medical school: Northwestern University Feinberg Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
NY license 199046
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 47
- Services billed
- 221
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 65 | 33 |
| Insertion of needle into vein for collection of blood sample | 53 | 26 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 50 | 18 |
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Jardiance (empagliflozin) Other prescribers in New York, NY | 39 |
| Metformin Hcl Er (metformin hcl) Other prescribers in New York, NY | 35 |
| Levothyroxine Sodium Other prescribers in New York, NY | 34 |
| Ozempic (semaglutide) Other prescribers in New York, NY | 32 |
| Atorvastatin Calcium Other prescribers in New York, NY | 26 |
| Novolog (insulin aspart) Other prescribers in New York, NY | 26 |
| Nano 2nd Gen Pen Needle (pen needle, diabetic) Other prescribers in New York, NY | 21 |
| Metformin Hcl Other prescribers in New York, NY | 21 |
| Losartan Potassium Other prescribers in New York, NY | 20 |
| Humalog (insulin lispro) Other prescribers in New York, NY | 19 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $8,308 in total to this clinician.
| Mannkind Corporation | $4,116 |
|---|---|
| Tandem Diabetes Care, Inc. | $3,216 |
| Insulet Corporation | $815 |
| Dexcom, Inc. | $161 |
| Honoraria | $3,826 |
|---|---|
| Consulting Fee | $2,789 |
| Food and Beverage | $1,473 |
| Travel and Lodging | $220 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Sep 27, 2025 | Honoraria AFREZZA · DIABETES MEDICINE | $3,826 |
| Tandem Diabetes Care, Inc. May 8, 2025 | Consulting Fee t:slim X2 Insulin Pump with Control-IQ · Endocrinology Company’s descriptionConsulting Agreements File | $1,000 |
| Tandem Diabetes Care, Inc. Aug 21, 2025 | Consulting Fee t:slim X2 Insulin Pump with Control-IQ · Endocrinology Company’s descriptionConsulting Agreements File | $1,000 |
| Insulet Corporation Jul 18, 2025 | Consulting Fee OMNIPOD · Insulin Pump | $789 |
| Mannkind Corporation Sep 27, 2025 | Travel and Lodging AFREZZA · DIABETES MEDICINE · travel to DALLAS, TX | $220 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $238,146 in research payments for these studies, mostly to the institutions running them.
- Innovative Automated Insulin Delivery System for Type 2 Diabetes
Sequel Med Tech, LLC · Completed · NCT06853990 - Continuous, real-time, remote monitoring of vital signs with telehealth to prevent readmissions for dysglycemia (telehealth)
Dexcom, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.